Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Tamoxifen-associated venous thrombosis and activated protein C resistance due to factor V Leiden.

Cancer - 15 May 1997

Weitz I C, Israel V K, Liebman H A

Abstract excerpt

BACKGROUND: Thromboembolic events are well recognized complications of cancers and their treatment. Tamoxifen, an antiestrogen used in the treatment of breast carcinoma and other malignancies, has been associated with thrombotic events. Activated protein C resistance due to Factor V Leiden is the most prevalent inherited prothrombotic defect in populations of European descent and has been reported as a major...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Breast Neoplasms
Share to Factor V

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Heterozygote

Share to Melanoma

Share to Mutation

Share to Protein C

Share to Skin Neoplasms

Source

Identifiers

PMID: 9149031

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Tamoxifen-associated venous thrombosis and activated protein C resistance due to factor V Leiden.PMID 9149031Read ↗

Factor V Leiden mutation and thromboembolism risk in women receiving adjuvant tamoxifen for breast cancer.Semantic proximity Read ↗

Factor V Leiden mutation and high FVIII are associated with an increased risk of VTE in women with breast cancer during adjuvant tamoxifen - results from a prospective, single center, case control study.Semantic proximity Read ↗

Effect of Factor V Leiden and prothrombin G20210-->A mutations on thromboembolic risk in the national surgical adjuvant breast and bowel project breast cancer prevention trial.Semantic proximity Read ↗

Acquired activated protein C resistance is common in cancer patients and is associated with venous thromboembolism.Semantic proximity Read ↗

Acquired and inherited risk factors for developing venous thromboembolism in cancer patients receiving adjuvant chemotherapy: a prospective trial.Semantic proximity Read ↗

The factor V leiden mutation and the risk of venous thromboembolism in gynecologic oncology patients1.Semantic proximity Read ↗

Activated protein C resistance and factor V Leiden mutation are independent risk factors for venous thromboembolism.Semantic proximity Read ↗

Prothrombotic mutations, hormone therapy, and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration.Semantic proximity Read ↗

Activated protein C resistance (factor V Leiden) associated with thrombosis in pregnancy.Semantic proximity Read ↗

Activated protein C resistance and adverse pregnancy outcome.Semantic proximity Read ↗

Life threatening pulmonary embolus in a factor V Leiden carrier on oral contraceptives: a case report.Semantic proximity Read ↗

Factor V Leiden, hormone replacement therapy, and risk of venous thromboembolic events in women with coronary disease.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.